11 stories mentioning SHA:688506
Every FINWIRES story that references SHA:688506, newest first.
Sichuan Biokin Pharmaceutical (SHA:688506) received China's regulatory approval to conduct clinical trials of its BL-M14D1 injection.The clinical trials will focus on the drug in combination with PD-1/PD-L1 inhibitors for extensive-stage small cell lung cancer, according to a Monday filing with the Shanghai bourse.Shares of the drugmaker were up 1% in recent trade.
Sichuan Biokin Pharmaceutical (SHA:688506) said China's Center for Drug Evaluation has accepted the new drug application for iza-bren for treating breast cancer.The submission follows a Phase Three trial where iza-bren met dual primary endpoints of progression-free and overall survival, according to a Monday filing with the Shanghai bourse.Shares of the drugmaker were up 3% in recent trade.
Sichuan Biokin Pharmaceutical (SHA:688506) received approval from China's National Medical Products Administration for the clinical trials of combination therapies with the drug, BL-M14D1 (DLL3ADC), according to a Shanghai bourse filing on Monday.The regulator allows the drug to be tested with PD-L1 monoclonal antibodies, anti-angiogenic agents and chemotherapy for the treatment of small cell lung cancer.The drugmaker's shares rose 2% during the morning trade Monday.
Sichuan Biokin Pharmaceutical (SHA:688506) obtained clearance from the U.S. Food and Drug Administration for its Phase Three clinical trial application for BL-M14D1 combined with immunotherapy as a first-line treatment for extensive-stage small cell lung cancer, according to a Tuesday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 1% in recent trade.
Sichuan Biokin Pharmaceutical (SHA:688506) obtained a commitment letter for a 180 million yuan, three-year loan from Bank of China (HKG:3988, SHA:601988) for its share repurchase program, according to a Saturday filing with the Shanghai bourse.The drug company plans to repurchase between 100 million yuan and 200 million yuan of shares at 398 yuan apiece.
China's drug regulator approved Sichuan Biokin Pharmaceutical's (SHA:688506) clinical trial for its BL-M08D1 injection as a combination therapy for diffuse large B-cell lymphoma, according to a Friday filing with the Shanghai bourse.Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma, according to the Mayo Clinic.BL-M08D1 is also undergoing phase 1B trials for relapsed or refractory hematologic malignancies and locally advanced tumors.
Sichuan Biokin Pharmaceutical (SHA:688506) completed the enrollment of its first subject in the Phase III clinical trial on BL-M05D1 injection, according to a Shanghai bourse filing on Friday.The drug is being tested as a treatment for patients with Claudin18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma who have previously received first-line therapy.
Sichuan Biokin Pharmaceutical (SHA:688506) received approval from China's National Medical Products Administration for the clinical trial of a combination therapy with iza-bren for injection (BL-B01D1), according to a Shanghai bourse filing on Wednesday.The drug will be tested in combination with small-molecule targeted therapies for the treatment of non-small cell lung cancer.
Sichuan Biokin Pharmaceutical (SHA:688506) enrolled the first subject for the Phase III clinical trial of T-Bren, according to a Shanghai bourse filing on Wednesday.The drug is being tested in combination with pertuzumab and trastuzumab for the treatment of HER2-positive recurrent or metastatic breast cancer.
Sichuan Biokin Pharmaceutical (SHA:688506) reported a 128% decrease in net profit in 2025 to 1.05 billion yuan from 3.71 billion yuan a year earlier.Earnings per share plunged to 2.61 yuan from 9.25 yuan, the pharmaceutical company said in a Shanghai bourse filing on Tuesday.Revenue slumped 57% to 2.52 billion yuan from 5.82 billion yuan.Biokin attributed the lackluster performance to a high comparison base as the revenue generated in 2024 benefited from the intellectual property cooperation agreement it reached with BMS on a product called Iza-bren.Shares of the company fell 3% in recent trade.
Sichuan Biokin Pharmaceutical's (SHA:688506) attributable net loss ballooned to 774.6 million yuan in the first quarter from 531.4 million yuan a year earlier.Loss per share likewise widened to 1.88 yuan from 1.33 yuan, the pharmaceutical company said in a Shanghai bourse filing on Tuesday.Revenue, however, jumped 40% to 94.6 million yuan from 67.4 million yuan, which Biokin attributed to increased market demand for its products.Shares of the company fell nearly 3% in recent trade.